Compare Amphastar Pharmaceuticals Inc (AMPH) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Energy Select Sector SPDR Fund — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Energy Select Sector SPDR Fund trades at $55.84. The key difference: Energy Select Sector SPDR Fund is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | XLE | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | — |
52-Week High | $30.81 | $62.57 |
52-Week Low | $16.87 | $42.12 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
XLE, the Energy Select Sector SPDR ETF, trades at $55.08, up 0.49% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF has gained 21% year-to-date as of July 2, 2026 (ETF Trends), benefiting from oil price volatility and geopolitical tensions. Recent news highlights sector strength, though oil price fluctuations and concentration in 21 holdings pose considerations.
Outlook remains supported by energy demand and disciplined capital expenditure, but risks include oil price sensitivity and political pressure. Analyst sentiment is mixed, with technical strength offsetting fundamental valuation gaps. The dividend yield and expense ratio advantages are positive, yet investors face volatility from crude market dynamics and election-related policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
